In this insightful episode, The Oncology Brothers are joined by Dr. Eric Singhi, Assistant Professor – University of Texas, MD Anderson Cancer Center, to discuss a treatment algorithm for metastatic non-small cell lung cancer without targetable mutations in the first-line setting.
Assessing an Algorithm for Metastatic Non-Small Cell Lung Cancer Without Targetable Mutations
By Oncology Brothers - Last Updated: March 22, 2023Related Posts
The efficacy of zongertinib was evaluated in Beamion LUNG-1, an open-label, multicenter, multi-cohort trial.
FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 ...
Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall ...
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Latest News
Physician's Weekly
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.